cladribine / Generic mfg. - LARVOL DELTA

Outcomes in patients with newly diagnosed Acute Myeloid Leukemia with KMT2A rearrangement treated with cladribine, idarubicin, cytarabine (CLIA) with or without venetoclax (ASH 2025) - P2 | "The 2-year EFS was 81% and 50% for CLIA-Ven and CLIA, respectively (HR 0.28, p=0.09).The 2-year OS was 81% and 50% for CLIA-Ven and CLIA, respectively (HR 0.37, p=0.19).There were a total of 3 deaths in the CLIA arm: 1 death was treatment related mortality on day 10 of firstcycle of the CLIA due to DAH and intracranial bleed and two deaths were secondary to relapsed disease.There were 3 deaths in CLIA-Ven arm: 1 death was due to severe COVID-19 related complication after 2cycles of chemo, 1 death due to infectious complications 21 days post Allo SCT and 1 death was due torelapsed disease. ConclusionAmong young and fit patients with newly diagnosed AML with KMT2Ar, IC with CLIA induced high rates ofMRD negative remissions, allowing a majority of patients to proceed with a potentially curative alloSCT.The addition of venetoclax with CLIA appeared to produce a higher rate of MRD negative completeremission, low rate of relapse, and promising long term survival in a high..."

Clinical • IO biomarker • Acute Myelogenous Leukemia • Hematological Malignancies • Infectious Disease • Leukemia • Novel Coronavirus Disease • CDKN1A • KMT2A • KRAS • NRAS • TET2

The Regimen of Cladribine, Cytarabine, and Venetoclax (CAV) Induces Apoptosis in Acute Myeloid Leukemia Cells by Enhancing DNA Damage. (PubMed, J Vis Exp) - "Mechanistically, CAV exerts potent anti-AML effects by synergistically exacerbating DNA damage, inducing apoptosis, arresting the cell cycle at the G0/G1 phase, and promoting differentiation of AML cells toward myeloid/monocyte-macrophage lineages. Collectively, these findings confirm the efficacy of CAV and delineate its multifaceted mechanism of action, thereby providing a well-supported, mechanism-driven combinatorial therapeutic strategy for the management of AML."

Journal • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • Transplantation

Cladribine, low-dose cytarabine, and venetoclax in newly diagnosed and relapsed/refractory acute myeloid leukemia: A global perspective. (PubMed, Curr Res Transl Med) - "CLAD-LDAC-venetoclax was highly effective in newly diagnosed AML, but had limited response durability in the R/R setting, particularly post-venetoclax exposure. These findings support its role as an induction strategy for unfit patients and highlight the need for novel salvage approaches in R/R AML."

Journal • Acute Myelogenous Leukemia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Oncology • Transplantation

Phase II Study of Cladribine with Low Dose Cytarabine and Venetoclax Alternating with Azacytidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia (ASH 2024) - P2 | "Conclusions : CLAD-LDAC-VEN alternating with AZA + VEN produces an excellent rate of CR/CRi with high rates of MRD negativity , translating into favorable long term OS and EFS in patients aged ≥ 60 yrs or those unfit for intensive chemotherapy. Benefit was seen across most genomically defined subgroups, including those with RAS mutations, where an HMA-Ven alone approach is associated with a mOS of 12 months."

P2 data • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • Oncology • DDX41 • DNMT3A • FLT3 • KRAS • NPM1 • TET2 • TP53

The effect of cladribine-containing conditioning regimen on the efficacy and safety of allogeneic hematopoietic stem cell transplantation for children with acute lymphoblastic leukemia. (PubMed, Stem Cell Res Ther) - "Incorporation cladribine into conditioning regimens for pediatric ALL is associated with improved relapse-free survival and significantly lower frequencies of renal and gastrointestinal toxicities, without increasing the risk of transplant-related complications. Given the retrospective design and limited number of events, these promising findings warrant prospective validation in future studies."

Journal • Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Oncology • Pediatrics • Transplantation

Cladribine, idarubicin, and cytarabine (CLIA) for patients with relapsed and/or refractory acute myeloid leukemia: A single-center, single-arm, phase 2 trial. (PubMed, Cancer) - P2 | "CLIA is effective for patients with R/R AML and offers a safety profile similar to that of other intensive regimens (ClinicalTrials.gov identifier NCT02115295)."

Journal • P2 data • Acute Myelogenous Leukemia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Oncology • Transplantation • FLT3

OUTCOMES OF ADULT PATIENTS WITH NEWLY DIAGNOSED IDH-MUTATED ACUTE MYELOID LEUKEMIA RECEIVING INTENSIVE CHEMOTHERAPY PLUS VENETOCLAX (EHA 2025) - P1/2, P2 | "This was a retrospective pooled analysis of two clinical trials of cladribine, idarubicin, and cytarabine + VEN (CLIA+VEN, NCT02115295) and fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin + VEN (FLAG-IDA+VEN, NCT03214562). Venetoclax combined with IC results in a high rate of MRD-negative remissions and impressive OS in newly diagnosed, IDH-mutated AML. IDH1-mutated AML had lower response rates and OS, possibly due to a higher proportion of concurrent adverse cytomolecular features. Randomized trials are needed to determine the optimal induction regimen for patients with IDH mutations."

Clinical • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • IDH1

PHASE II STUDY OF CLADRIBINE WITH LOW DOSE CYTARABINE AND VENETOCLAX ALTERNATING WITH AZACYTIDINE AND VENETOCLAX FOR NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (EHA 2025) - P2 | "CLAD-LDAC-VEN alternating with AZA + VEN produces a high rate of MRD- CRc, translating into favorable long-term outcomes in patients aged ≥ 60 yrs or those unfit for intensive chemotherapy. A high rate of pts successfully moving to SCT advocates exploring this regimen in more fit individuals."

P2 data • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • Oncology • DDX41 • DNMT3A • FLT3 • KRAS • NPM1 • TET2 • TP53

Myeloablative fractionated busulfan, fludarabine, cladribine, thiotepa, and venetoclax (Cladillac) conditioning for high-risk AML: A phase 2 trial (ASH 2025) - P2/3 | "To reduce GVHD-associated morbidity and mortality, weincorporated post-transplant cyclophosphamide (PTCy)...GVHD prophylaxis consisted of PTCy 50mg/kg on days +3 and +4, tacrolimus ± mycophenolate mofetil... This study met its primary endpoint, demonstrating a promising 3-year PFS of 58% in acohort of patients with very high-risk AML. Outcomes were particularly favorable in TP53 wild-typepatients, with a low relapse rate of 13% and 3-year OS of 74%. These findings support furtherinvestigation of this novel conditioning regimen."

P2 data • Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • FLT3 • TP53

UNRAVELING ACUTE ST ELEVATION IN A YOUNG PATIENT WITH LEUKEMIA AND SEVERE THROMBOCYTOPENIA (ACC 2026) - "Background: A 36-year-old male with leukemic myocardial infiltrate from acute myelomonocytic leukemia developed chest pain 4 days after Cladribine, Cytarabine, Venetoclax, and Gemtuzumab. In patients with leukemic myocardial infiltrates, myocardial injury may follow oncologic treatment response. The mechanism is hypothesized as "collateral damage" of myocardial cells from inflammatory necrosis of adjacent leukemic cells. It results in STE resembling infarction, but without plaque rupture."

Clinical • Hematological Disorders • Hematological Malignancies • Leukemia • Thrombocytopenia

Fusarium on the Surface: Cutaneous Clues to a Deadly Disseminated Infection (AAD 2026) - "Patient History: Here we present a 68-year-old man with past medical history of acute myeloid leukemia (AML) treated with an allogeneic stem cell transplant, chronic hepatic graft-versus-host disease (GVHD), and cutaneous and pulmonary mucormycosis, which had been successfully managed for two years with posaconazole, who was admitted for chemotherapy with cladribine, cytarabine, and venetoclax...Treatment: Management included surgical nasal sinus debridement and near-total ethmoidectomy, in addition to aggressive systemic antifungal therapy with voriconazole, liposomal amphotericin B, micafungin, and oral terbinafine. Supportive treatment included meropenem and filgrastim to address concurrent neutropenia... In immunocompromised patients with hematologic malignancies, dermatologists should have a low threshold to perform biopsies and tissue cultures on even non-specific skin findings. Prompt dermatologic evaluation, biopsy, and tissue culture are essential for early..."

Acute Myelogenous Leukemia • Graft versus Host Disease • Hematological Malignancies • Hepatology • Immunology • Infectious Disease • Leukemia • Liver Failure • Neutropenia • Otorhinolaryngology

EFFICACY OF THE TRIPLET THERAPY WITH VENETOCLAX, AZACITIDINE AND GILTERITINIB FOR THE TREATMENT OF FLT3-ITD MUTATED R/R AML PATIENTS BRIDGING TO ALLOGENEIC STEM CELL TRANSPLANTATION (EBMT 2026) - "Patients received myeloablative conditioning with a modified Bu/Cy/Cla/Ara-c (busulfan/cyclophosphamide/cladribine/cytarabine) or MCBC (melphalan/cladribine/busulfan/cyclophosphamide) preparative regimen. The triplet therapy of VEN, AZA and gilteritinib resulted in high rates of CR/CRi and enhanced the feasibility of HSCT in FLT3-ITD mutated AML patients with R/R disease or persistent MRD. Sequential allo-HSCT followed by gilteritinib maintenance therapy may significantly improve the long-term prognosis in this high-risk group of patients."

Clinical • Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Infectious Disease • Leukemia • Transplantation • FLT3

SALVAGE ALLOGENEIC STEM CELL TRANSPLANTATION FOR RELAPSED/REFRACTORY AML: CLADRIBINE-BASED INTENSIVE CONDITIONING VERSUS STANDARD MYELOABLATIVE REGIMENS (EBMT 2026) - "Cladribine-based regimen consisted of cladribine 5 mg/m2/day and high-dose cytarabine 2 g/m2/day for 3 days followed by Bu/Cy-based MAC regimen. This study demonstrated that a cladribine-based intensive regimen achieved comparable clinical outcomes to standard Bu/Cy MAC regimen in salvage HSCT for R/R AML, but may increase the risk of early NRM. Furthermore, for these patients, prophylactic DLI post-HSCT effectively reduced the risk of relapse, thus improving overall survival."

Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Acute Promyelocytic Leukemia • Bone Marrow Transplantation • Chronic Myeloid Leukemia • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Myelodysplastic Syndrome • Transplantation

ARCHIVE CONDITIONING (ALKYLATING AGENTS, CYTARABINE, CLADRIBINE, HYPOMETHYLATING AGENTS, AND VENETOCLAX) FOR UPFRONT ALLOGENEIC STEM CELL TRANSPLANTATION IN NEWLY DIAGNOSED OR RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (EBMT 2026) - "The patients were 18 years or older, had AML or MDS/AML with >5% blasts and/or extramedullary disease, and were alloSCT-eligible.ARCHIVE conditioning regimen (Picture 1) consisted of cytarabine 500 or 1000 mg/m2, cladribine 5 mg/m2 on days -8, -7, -6, -5, -4, venetoclax 600 mg/d and decitabine 20 mg/m2 / azacitidine 75 mg/m2 on days -8, -7, -6, -5, -4, -3, -2. The backbone alkylating agent was either busulfan (3.2 mg/kg on days -3 and/or -2) or melphalan (100 mg/m2 on day -2 in patients with previous busulfan exposure and/or TP53-mutated disease), whereas thiotepa was added to busulfan or melphalan in selected cases...GVHD prophylaxis consisted of cyclophosphamide 40 mg/kg (days +3, +4), calcineurin inhibitor, and mycophenolate mofetil.We collected baseline characteristics, CR+CRp rate at day +30, MRD negativity rate (by MFC and PCR), time-to-engraftment, grade 3-5 non-hematological toxicity (CTCAE v5.0), OS, and RFS.Picture 1. ARCHIVE conditioning regimen Thirty-two..."

Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Graft versus Host Disease • Hepatology • Immunology • Mucositis • Transplantation • FLT3 • TP53

CLADRIBINE WITH TOTAL BODY IRRADIATION AS A STRATEGY TO OPTIMIZE CONDITIONING REGIMEN IN AML AND MDS: A PROSPECTIVE STUDY OF THE POLISH ADULT LEUKEMIA GROUP (EBMT 2026) - "Both cladribine and Ara-C enhance Ara-CTP levels in leukemia blasts; however, only cladribine exhibits direct cytotoxic and hypomethylating effects, which accounts for the observed differences in efficacy. The myeloablative conditioning regimen consisting of TBI combined with cladribine may contribute to improved outcomes following allo-HCT for patients with AML and MDS."

Clinical • Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Myelodysplastic Syndrome

EFFICACY AND SAFETY OF MELPHALAN/TBI-BASED CONDITIONING REGIMENS (MCAC/TCAC) FOR AUTOLOGOUS HSCT IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA: A MULTICENTER, PROSPECTIVE COHORT STUDY (EBMT 2026) - P=N/A | "The MCAC regimen comprised melphalan (70 mg/m², days -8, -7), cyclophosphamide (40 mg/kg, days -6, -5), and cladribine (5 mg/m²) plus cytarabine (2 g/m²) on days -4 to -2. These preliminary findings suggest that the MCAC regimen appears to be a viable and safe alternative to TBI-based conditioning for auto-HSCT in adult ALL patients who achieve and sustain early MRD negativity. However, as enrollment in the TBI-based conditioning arm is not yet complete and the follow-up duration for both groups remains short, long-term efficacy and safety require further investigation."

Clinical • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Central Nervous System Leukemia • Cerebral Hemorrhage • Gastroenterology • Hematological Disorders • Hematological Malignancies • Hepatology • Leukemia • Liver Failure • Mucositis • Stomatitis • T Acute Lymphoblastic Leukemia

THE EFFICACY AND SAFETY OF MODIFIED MELPHALAN AND BUSULFAN-BASED REGIMEN FOR ALLOGENEIC TRANSPLANTATION IN PATIENTS WITH REFRACTORY/RELAPSED OR PERSISTENT MRD POSITIVE AML (EBMT 2026) - P=N/A | "In this study, we adopted a modified conditioning regimen comprising dual alkylating agents, which was named as MCBC (the combination of melphalan, cladribine, busulfan, and cyclophosphamide)...Rabbit ATG was added in haploid-identical and unrelated-matched donor transplantation. Early initiation of maintenance therapy is recommended if the patient's condition is stable after transplantation, including low-dose azacytidine, venetoclax, FLT3 inhibitors or chidamide... Our study confirms the excellent anti-leukemic capacity and favorable tolerability of MCBC conditioning regimen in patients with R/R or persistent MRD positive AML. Furthermore, the importance of early initiation of maintenance therapy post-transplantation for improving patient survival is underscored."

Clinical • Minimal residual disease • Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Mucositis • Transplantation

BUSULFAN PLUS CLADRIBINE COMPARED WITH BUSULFAN PLUS FLUDARABINE CONDITIONING REGIMEN FOR ACUTE MYELOID LEUKEMIA UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (EBMT 2026) - "In this study, the OS, DFS, CIR and NRM did not differ significantly between BuClad and BuFlu groups."

Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Leukemia • Transplantation

EFFICACY OF THE TRIPLET THERAPY WITH VENETOCLAX, AZACITIDINE AND GILTERITINIB FOR THE TREATMENT OF FLT3-ITD MUTATED R/R AML PATIENTS BRIDGING TO ALLOGENEIC STEM CELL TRANSPLANTATION (EBMT 2026) - "Patients received myeloablative conditioning with a modified Bu/Cy/Cla/Ara-c (busulfan/cyclophosphamide/cladribine/cytarabine) or MCBC (melphalan/cladribine/busulfan/cyclophosphamide) preparative regimen. The triplet therapy of VEN, AZA and gilteritinib resulted in high rates of CR/CRi and enhanced the feasibility of HSCT in FLT3-ITD mutated AML patients with R/R disease or persistent MRD. Sequential allo-HSCT followed by gilteritinib maintenance therapy may significantly improve the long-term prognosis in this high-risk group of patients."

Clinical • Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Infectious Disease • Leukemia • Transplantation • FLT3

SALVAGE ALLOGENEIC STEM CELL TRANSPLANTATION FOR RELAPSED/REFRACTORY AML: CLADRIBINE-BASED INTENSIVE CONDITIONING VERSUS STANDARD MYELOABLATIVE REGIMENS (EBMT 2026) - "Cladribine-based regimen consisted of cladribine 5 mg/m2/day and high-dose cytarabine 2 g/m2/day for 3 days followed by Bu/Cy-based MAC regimen. This study demonstrated that a cladribine-based intensive regimen achieved comparable clinical outcomes to standard Bu/Cy MAC regimen in salvage HSCT for R/R AML, but may increase the risk of early NRM. Furthermore, for these patients, prophylactic DLI post-HSCT effectively reduced the risk of relapse, thus improving overall survival."

Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Acute Promyelocytic Leukemia • Bone Marrow Transplantation • Chronic Myeloid Leukemia • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Myelodysplastic Syndrome • Transplantation

CLADRIBINE WITH TOTAL BODY IRRADIATION AS A STRATEGY TO OPTIMIZE CONDITIONING REGIMEN IN AML AND MDS: A PROSPECTIVE STUDY OF THE POLISH ADULT LEUKEMIA GROUP (EBMT 2026) - "Both cladribine and Ara-C enhance Ara-CTP levels in leukemia blasts; however, only cladribine exhibits direct cytotoxic and hypomethylating effects, which accounts for the observed differences in efficacy. The myeloablative conditioning regimen consisting of TBI combined with cladribine may contribute to improved outcomes following allo-HCT for patients with AML and MDS."

Clinical • Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Myelodysplastic Syndrome

EFFICACY AND SAFETY OF MELPHALAN/TBI-BASED CONDITIONING REGIMENS (MCAC/TCAC) FOR AUTOLOGOUS HSCT IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA: A MULTICENTER, PROSPECTIVE COHORT STUDY (EBMT 2026) - P=N/A | "The MCAC regimen comprised melphalan (70 mg/m², days -8, -7), cyclophosphamide (40 mg/kg, days -6, -5), and cladribine (5 mg/m²) plus cytarabine (2 g/m²) on days -4 to -2. These preliminary findings suggest that the MCAC regimen appears to be a viable and safe alternative to TBI-based conditioning for auto-HSCT in adult ALL patients who achieve and sustain early MRD negativity. However, as enrollment in the TBI-based conditioning arm is not yet complete and the follow-up duration for both groups remains short, long-term efficacy and safety require further investigation."

Clinical • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Central Nervous System Leukemia • Cerebral Hemorrhage • Gastroenterology • Hematological Disorders • Hematological Malignancies • Hepatology • Leukemia • Liver Failure • Mucositis • Stomatitis • T Acute Lymphoblastic Leukemia

THE EFFICACY AND SAFETY OF MODIFIED MELPHALAN AND BUSULFAN-BASED REGIMEN FOR ALLOGENEIC TRANSPLANTATION IN PATIENTS WITH REFRACTORY/RELAPSED OR PERSISTENT MRD POSITIVE AML (EBMT 2026) - P=N/A | "In this study, we adopted a modified conditioning regimen comprising dual alkylating agents, which was named as MCBC (the combination of melphalan, cladribine, busulfan, and cyclophosphamide)...Rabbit ATG was added in haploid-identical and unrelated-matched donor transplantation. Early initiation of maintenance therapy is recommended if the patient's condition is stable after transplantation, including low-dose azacytidine, venetoclax, FLT3 inhibitors or chidamide... Our study confirms the excellent anti-leukemic capacity and favorable tolerability of MCBC conditioning regimen in patients with R/R or persistent MRD positive AML. Furthermore, the importance of early initiation of maintenance therapy post-transplantation for improving patient survival is underscored."

Clinical • Minimal residual disease • Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Mucositis • Transplantation

ARCHIVE CONDITIONING (ALKYLATING AGENTS, CYTARABINE, CLADRIBINE, HYPOMETHYLATING AGENTS, AND VENETOCLAX) FOR UPFRONT ALLOGENEIC STEM CELL TRANSPLANTATION IN NEWLY DIAGNOSED OR RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (EBMT 2026) - "The patients were 18 years or older, had AML or MDS/AML with >5% blasts and/or extramedullary disease, and were alloSCT-eligible.ARCHIVE conditioning regimen (Picture 1) consisted of cytarabine 500 or 1000 mg/m2, cladribine 5 mg/m2 on days -8, -7, -6, -5, -4, venetoclax 600 mg/d and decitabine 20 mg/m2 / azacitidine 75 mg/m2 on days -8, -7, -6, -5, -4, -3, -2. The backbone alkylating agent was either busulfan (3.2 mg/kg on days -3 and/or -2) or melphalan (100 mg/m2 on day -2 in patients with previous busulfan exposure and/or TP53-mutated disease), whereas thiotepa was added to busulfan or melphalan in selected cases...GVHD prophylaxis consisted of cyclophosphamide 40 mg/kg (days +3, +4), calcineurin inhibitor, and mycophenolate mofetil.We collected baseline characteristics, CR+CRp rate at day +30, MRD negativity rate (by MFC and PCR), time-to-engraftment, grade 3-5 non-hematological toxicity (CTCAE v5.0), OS, and RFS.Picture 1. ARCHIVE conditioning regimen Thirty-two..."

Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Graft versus Host Disease • Hepatology • Immunology • Mucositis • Transplantation • FLT3 • TP53

RESOLVE trial: Registry and clinical trial comparing standard intensity and reduced intensity treatment in patients with AML or CLL who do not have residual disease. (clinicaltrialsregister.eu) - P4 | N=289 | Recruiting | Sponsor: Medizinische Hochschule Hannover | N=128 ➔ 289

Enrollment change • Minimal residual disease • Acute Myelogenous Leukemia • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Myelodysplastic Syndrome • Non-Hodgkin’s Lymphoma • Oncology • Small Lymphocytic Lymphoma